Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture
- PMID: 11344046
- DOI: 10.1016/s8756-3282(01)00420-3
Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture
Abstract
A member of the tumor necrosis factor (TNF) family, receptor activator of nuclear factor kappaB ligand (RANKL; also known as ODF, OPGL, and TRANCE), plays critical roles in osteoclast differentiation and activation in the presence of macrophage colony-stimulating factor (M-CSF). Recently, TNF-alpha has also been shown to induce the formation of multinucleated osteoclast-like cells (MNCs) in the presence of M-CSF from mouse macrophages. We demonstrated that mononuclear preosteoclast-like cells (POCs) were formed in the presence of conditioned medium of osteoblastic cells in a rat bone marrow culture depleted of stromal cells. Using this culture system, in this study we examined whether TNF-alpha affects differentiation into POCs from hematopoietic progenitor cells. Human TNF-alpha (hTNF-alpha) markedly stimulated the formation of POCs. Moreover, a concentration as low as 0.005 ng/mL of hTNF-alpha increased the level of mRNA for calcitonin receptor (CTR) and cathepsin-K of POCs. The POCs induced by hTNF-alpha formed MNCs, which showed dentine-resorbing activity after coculture with primary osteoblasts. Stimulation was observed after 24 h of treatment with hTNF-alpha only on day 1 or day 2 of the culture. After 24 h of hTNF-alpha treatment, expression of the receptor activator of nuclear factor kappaB (RANK) mRNA was markedly increased. The addition of soluble RANKL (sRANKL) to the preformed POCs efficiently induced MNCs. Interestingly, treatment of bone marrow cells with hTNF-alpha and sRANKL synergistically augmented the formation of MNCs. This formation was abolished by the addition of human osteoprotegerin (hOPG). These results suggest that cooperation of TNF-alpha and RANKL is important for osteoclastogenesis.
Similar articles
-
Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.J Bone Miner Res. 2001 Nov;16(11):2074-81. doi: 10.1359/jbmr.2001.16.11.2074. J Bone Miner Res. 2001. PMID: 11697804
-
Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.J Bone Miner Res. 2000 Sep;15(9):1766-75. doi: 10.1359/jbmr.2000.15.9.1766. J Bone Miner Res. 2000. PMID: 10976996
-
Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.Bone. 1999 Nov;25(5):517-23. doi: 10.1016/s8756-3282(99)00210-0. Bone. 1999. PMID: 10574571
-
The molecular basis of osteoclast differentiation and activation.Novartis Found Symp. 2001;232:235-47; discussion 247-50. doi: 10.1002/0470846658.ch16. Novartis Found Symp. 2001. PMID: 11277084 Review.
-
A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55. doi: 10.1006/bbrc.1999.0252. Biochem Biophys Res Commun. 1999. PMID: 10080918 Review.
Cited by
-
Hepatic osteodystrophy.Clin Cases Miner Bone Metab. 2014 Sep;11(3):185-91. Clin Cases Miner Bone Metab. 2014. PMID: 25568651 Free PMC article. Review.
-
Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.Br J Pharmacol. 2014 Feb;171(3):663-75. doi: 10.1111/bph.12463. Br J Pharmacol. 2014. PMID: 24125472 Free PMC article.
-
Advances in the research on myokine-driven regulation of bone metabolism.Heliyon. 2023 Nov 20;10(1):e22547. doi: 10.1016/j.heliyon.2023.e22547. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38226270 Free PMC article. Review.
-
Cathepsin K in Pathological Conditions and New Therapeutic and Diagnostic Perspectives.Int J Mol Sci. 2022 Nov 9;23(22):13762. doi: 10.3390/ijms232213762. Int J Mol Sci. 2022. PMID: 36430239 Free PMC article. Review.
-
Serum cytokines and bone metabolic markers in patients with rheumatoid arthritis treated with biological disease modifying anti-rheumatic drugs.Clin Rheumatol. 2023 Mar;42(3):721-730. doi: 10.1007/s10067-022-06390-x. Epub 2022 Sep 26. Clin Rheumatol. 2023. PMID: 36163441
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials